Literature DB >> 32147409

Are children less susceptible to COVID-19?

Ping-Ing Lee1, Ya-Li Hu2, Po-Yen Chen3, Yhu-Chering Huang4, Po-Ren Hsueh5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32147409      PMCID: PMC7102573          DOI: 10.1016/j.jmii.2020.02.011

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


× No keyword cloud information.
Emerging at the end of 2019, coronavirus disease 2019 (COVID-19) has become a public health threat to people all over the world. The lower airway is the primary target of the infection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pneumonia is always present in patients with severe COVID-19. , Available reports to date show that COVID-19 seems to be uncommon in children.3, 4, 5, 6 Recent data reported from the Chinese Centers for Diseases Control and Prevention indicated that among the 44,672 confirmed cases of COVID-19 as of February 11, 2020, 416 (0.9%) were aged 0–10 years and 549 (1.2%) aged 10–19 years. Exploring the underlying reasons may help understand the pathogenesis of COVID-19. One possible reason is that children have fewer outdoor activities and undertake less international travel, making them less likely to contract the virus. The number of pediatric patients may increase in the future and a lower number of pediatric patients at the beginning of a pandemic does not necessarily mean that children are less susceptible to the infection. In fact, infants can be infected by SARS-CoV-2. During the 1918 outbreak of “Spanish flu,” those ≥65 years old and children ≤15 years experienced little or no change in excess mortality as compared with that of the previous influenza season. Nevertheless, those aged 15–24 and 25–44 years experienced sharply elevated death rates. Similarly, at the beginning of the 2009 pandemic H1N1 influenza outbreak, the percentage age distributions for mortality and morbidity for patients with severe pneumonia show a marked shift to persons between the ages of 5 and 59 years, as compared with distributions observed during previous periods of epidemic influenza. On the other hand, several infectious diseases are well known to be less severe in children. Paralytic polio occurred in approximately 1 in 1000 infections among infants, in contrast to approximately 1 in 100 infections among adolescents. As compared with young children, teenagers and adults tend to have symptomatic rubella more frequently and have systemic manifestations. The overall case-fatality rate of severe respiratory distress syndrome (SARS) ranges from 7% to 17%. Persons with underlying medical conditions and those older than 65 years of age had mortality rates as high as 50%. However, there was no mortality in children or in adults younger than the age of 24 years. The reasons for the relative resistance of children to some infectious diseases remains obscure. It was suggested that maturational changes in the axonal transport system may explain the relative resistance of immature mice to poliovirus-induced paralysis. Other suggested reasons include children having a more active innate immune response, healthier respiratory tracts because they have not been exposed to as much cigarette smoke and air pollution as adults, and fewer underlying disorders. A more vigorous immune response in adults may also explain a detrimental immune response that is associated with acute respiratory distress syndrome. A difference in the distribution, maturation, and functioning of viral receptors is frequently mentioned as a possible reason of the age-related difference in incidence. The SARS virus, SARS-CoV-2, and human coronavirus-NL63 (HCoV-NL63) all use the angiotensin-converting enzyme-2 (ACE2) as the cell receptor in humans. , Previous studies demonstrated that HCoV-NL63 infection is more common in adults than in children. , This finding suggests there may indeed be relative resistance to SARS-CoV-2 in children. ACE2 expression in rat lung has been found to dramatically decrease with age. This finding may not be consistent with a relatively low susceptibility of children to COVID-19. However, studies show that ACE2 is involved in protective mechanisms of the lung. It may protect against severe lung injury induced by respiratory virus infection in an experimental mouse model and in pediatric patients. ACE2 also protects against severe acute lung injury that can be triggered by sepsis, acid aspiration, SARS, and lethal avian influenza A H5N1 virus infection. These intriguing findings suggest that children may really be less susceptible to COVID-19. It is important to elucidate the underlying mechanism that may help to manage COVID-19 patients.

Declaration of Competing Interest

The author declares no conflicts of interest.
  17 in total

1.  Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City.

Authors:  Donald R Olson; Lone Simonsen; Paul J Edelson; Stephen S Morse
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-26       Impact factor: 11.205

2.  Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.

Authors:  Heike Hofmann; Krzysztof Pyrc; Lia van der Hoek; Martina Geier; Ben Berkhout; Stefan Pöhlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

3.  [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2020-02-10

4.  Pathogenesis of human poliovirus infection in mice. II. Age-dependency of paralysis.

Authors:  B Jubelt; O Narayan; R T Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1980-03       Impact factor: 3.685

5.  Age- and gender-related difference of ACE2 expression in rat lung.

Authors:  Xudong Xie; Xie Xudong; Junzhu Chen; Chen Junzhu; Xingxiang Wang; Wang Xingxiang; Furong Zhang; Zhang Furong; Yanrong Liu; Liu Yanrong
Journal:  Life Sci       Date:  2005-11-21       Impact factor: 5.037

6.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

7.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients.

Authors:  Kyoung Hwa Lee; Seul Gi Yoo; Yonggeun Cho; Da Eun Kwon; Yeonju La; Sang Hoon Han; Myoung Soo Kim; Jin Sub Choi; Soon Il Kim; Yu Seun Kim; Yoo Hong Min; June-Won Cheong; Jin Seok Kim; Yong Goo Song
Journal:  J Microbiol Immunol Infect       Date:  2019-06-19       Impact factor: 4.399

9.  Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus.

Authors:  Hongjing Gu; Zhengde Xie; Tieling Li; Shaogeng Zhang; Chengcai Lai; Ping Zhu; Keyu Wang; Lina Han; Yueqiang Duan; Zhongpeng Zhao; Xiaolan Yang; Li Xing; Peirui Zhang; Zhouhai Wang; Ruisheng Li; Jane J Yu; Xiliang Wang; Penghui Yang
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

10.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.

Authors:  Chih-Cheng Lai; Tzu-Ping Shih; Wen-Chien Ko; Hung-Jen Tang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2020-02-17       Impact factor: 5.283

View more
  175 in total

1.  COVID-19 in children: Current status.

Authors:  Mei-Jy Jeng
Journal:  J Chin Med Assoc       Date:  2020-04-15       Impact factor: 2.743

Review 2.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.

Authors:  Esteban Ortiz-Prado; Katherine Simbaña-Rivera; Lenin Gómez-Barreno; Mario Rubio-Neira; Linda P Guaman; Nikolaos C Kyriakidis; Claire Muslin; Ana María Gómez Jaramillo; Carlos Barba-Ostria; Doménica Cevallos-Robalino; Hugo Sanches-SanMiguel; Luis Unigarro; Rasa Zalakeviciute; Naomi Gadian; Andrés López-Cortés
Journal:  Diagn Microbiol Infect Dis       Date:  2020-05-30       Impact factor: 2.803

3.  June: open-source individual-based epidemiology simulation.

Authors:  Joseph Aylett-Bullock; Carolina Cuesta-Lazaro; Arnau Quera-Bofarull; Miguel Icaza-Lizaola; Aidan Sedgewick; Henry Truong; Aoife Curran; Edward Elliott; Tristan Caulfield; Kevin Fong; Ian Vernon; Julian Williams; Richard Bower; Frank Krauss
Journal:  R Soc Open Sci       Date:  2021-07-07       Impact factor: 2.963

Review 4.  A literature review of 2019 novel coronavirus (SARS-CoV2) infection in neonates and children.

Authors:  Matteo Di Nardo; Grace van Leeuwen; Alessandra Loreti; Maria Antonietta Barbieri; Yit Guner; Franco Locatelli; Vito Marco Ranieri
Journal:  Pediatr Res       Date:  2020-07-17       Impact factor: 3.756

5.  Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons.

Authors:  Amir Tajbakhsh; Khojaste Rahimi Jaberi; Seyed Mohammad Gheibi Hayat; Mehrdad Sharifi; Thomas P Johnston; Paul C Guest; Mohammad Jafari; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Interpreting, analysing and modelling COVID-19 mortality data.

Authors:  Didier Sornette; Euan Mearns; Michael Schatz; Ke Wu; Didier Darcet
Journal:  Nonlinear Dyn       Date:  2020-10-01       Impact factor: 5.022

Review 7.  Surgical Practice in the Shadow of COVID-19 Outbreak.

Authors:  Reza Abdi; Reza Shojaeian; Sara Hajian; Shahrzad Sheikh
Journal:  Arch Bone Jt Surg       Date:  2020-04

8.  Ventilatory Support in Patients with COVID-19.

Authors:  Paolo Maria Leone; Matteo Siciliano; Jacopo Simonetti; Angelena Lopez; Tanzira Zaman; Francesco Varone; Luca Richeldi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Distinctive clinical and laboratory features of COVID-19 and H1N1 influenza infections among hospitalized pediatric patients.

Authors:  Ali Alsuheel Asseri; Ayed A Shati; Saleh M Al-Qahtani; Ibrahim A Alzaydani; Ahmed A Al-Jarie; Mohammed J Alaliani; Abdelwahid Saeed Ali
Journal:  World J Pediatr       Date:  2021-05-10       Impact factor: 2.764

Review 10.  Pathophysiology of COVID-19: Why Children Fare Better than Adults?

Authors:  Nitin Dhochak; Tanu Singhal; S K Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2020-05-14       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.